BioCentury | Oct 13, 2017
Clinical News

Athera begins Phase IIa trial of PC-mAb for arterial inflammation

...vivo , arterial wall stiffness and safety. PC-mAb is a human mAb against phosphorylcholine (PC). Athera Biotechnologies AB...
...assessed in vivo , arterial wall stiffness and safety Status: Phase IIa started Milestone: NA Jennie Walters PC-mAb Athera Biotechnologies AB Phosphorylcholine...
BioCentury | Oct 13, 2017
Financial News

Athera raises SEK57M

...In late August, cardiovascular company Athera Biotechnologies AB (Stockholm, Sweden) raised SEK57 million ($7.2 million) in a financing...
...Ribbskottet AB. Athera´s management team and Antaros Medical AB also participated. Athera Biotechnologies AB , Stockholm, Sweden Jennie Walters Athera Biotechnologies AB...
BioCentury | Dec 15, 2014
Company News

Athera, Boehringer Ingelheim deal

...and pipeline. Athera plans report data from a Phase I trial of PC-mAb in 3Q15. Athera...
...no termination fee. Athera declined to disclose additional financial details (see BioCentury, June 24, 2013). Athera Biotechnologies AB...
BioCentury | May 26, 2014
Emerging Company Profile

Annexin: Attenuating vascular inflammation

...hands before finding a home at Annexin. In 2005, Karolinska licensed IP covering ANXA5 to Athera Biotechnologies AB...
...a company developing anti-inflammatory therapeutics for cardiovascular diseases based on separate research from Karolinska. However, Athera...
...and postoperative complications, with two sets of patents issued in Europe. Companies and Institutions Mentioned Athera Biotechnologies AB...
BioCentury | Sep 30, 2013
Company News

Athera board of directors update

Athera Biotechnologies AB , Stockholm, Sweden Business: Cardiovascular Appointed: Gunnar Olsson as chairman, formerly head of the global cardiovascular and gastrointestinal disease team at AstraZeneca plc ; he replaces Per Sjoberg, who resigned WIR Staff Cardiovascular...
BioCentury | Jul 11, 2013
Translation in Brief

Translational tidbits

...tuberculosis and neglected tropical diseases within the framework of the Global Health Innovative Technology Fund Athera Biotechnologies AB...
...€6 million ($8 million) Grant from EU's Seventh Framework Program to CARDIMMUN consortium for developing Athera's...
BioCentury | Jun 24, 2013
Company News

Athera, Boehringer Ingelheim deal

...Boehringer received an exclusive option from Athera to PC-mAb , a human preclinical mAb against phosphorylcholine...
...to treat patients with cardiovascular disease at an increased risk for secondary events and death. Athera...
...declined to disclose financial details. Karolinska Development AB (SSE:KDEV, Solna, Sweden) owns 65% of Athera. Athera Biotechnologies AB...
BioCentury | Jun 24, 2013
Company News

Athera cardiovascular news

...€6 million ($8 million) to the CARDIMMUN consortium to develop the product through proof-of-concept development. Athera...
...is in late preclinical development. Karolinska Development AB (SSE:KDEV, Solna, Sweden) owns 65% of Athera. Athera Biotechnologies AB...
BioCentury | Oct 6, 2008
Company News

Athera, Dyax deal

...diseases such as atherosclerosis. Dyax will use its antibody libraries to generate human mAbs, and Athera...
...will have the option to further co-develop and commercialize candidates. Financial terms were not disclosed. Athera Biotechnologies AB...
Items per page:
1 - 9 of 9
BioCentury | Oct 13, 2017
Clinical News

Athera begins Phase IIa trial of PC-mAb for arterial inflammation

...vivo , arterial wall stiffness and safety. PC-mAb is a human mAb against phosphorylcholine (PC). Athera Biotechnologies AB...
...assessed in vivo , arterial wall stiffness and safety Status: Phase IIa started Milestone: NA Jennie Walters PC-mAb Athera Biotechnologies AB Phosphorylcholine...
BioCentury | Oct 13, 2017
Financial News

Athera raises SEK57M

...In late August, cardiovascular company Athera Biotechnologies AB (Stockholm, Sweden) raised SEK57 million ($7.2 million) in a financing...
...Ribbskottet AB. Athera´s management team and Antaros Medical AB also participated. Athera Biotechnologies AB , Stockholm, Sweden Jennie Walters Athera Biotechnologies AB...
BioCentury | Dec 15, 2014
Company News

Athera, Boehringer Ingelheim deal

...and pipeline. Athera plans report data from a Phase I trial of PC-mAb in 3Q15. Athera...
...no termination fee. Athera declined to disclose additional financial details (see BioCentury, June 24, 2013). Athera Biotechnologies AB...
BioCentury | May 26, 2014
Emerging Company Profile

Annexin: Attenuating vascular inflammation

...hands before finding a home at Annexin. In 2005, Karolinska licensed IP covering ANXA5 to Athera Biotechnologies AB...
...a company developing anti-inflammatory therapeutics for cardiovascular diseases based on separate research from Karolinska. However, Athera...
...and postoperative complications, with two sets of patents issued in Europe. Companies and Institutions Mentioned Athera Biotechnologies AB...
BioCentury | Sep 30, 2013
Company News

Athera board of directors update

Athera Biotechnologies AB , Stockholm, Sweden Business: Cardiovascular Appointed: Gunnar Olsson as chairman, formerly head of the global cardiovascular and gastrointestinal disease team at AstraZeneca plc ; he replaces Per Sjoberg, who resigned WIR Staff Cardiovascular...
BioCentury | Jul 11, 2013
Translation in Brief

Translational tidbits

...tuberculosis and neglected tropical diseases within the framework of the Global Health Innovative Technology Fund Athera Biotechnologies AB...
...€6 million ($8 million) Grant from EU's Seventh Framework Program to CARDIMMUN consortium for developing Athera's...
BioCentury | Jun 24, 2013
Company News

Athera, Boehringer Ingelheim deal

...Boehringer received an exclusive option from Athera to PC-mAb , a human preclinical mAb against phosphorylcholine...
...to treat patients with cardiovascular disease at an increased risk for secondary events and death. Athera...
...declined to disclose financial details. Karolinska Development AB (SSE:KDEV, Solna, Sweden) owns 65% of Athera. Athera Biotechnologies AB...
BioCentury | Jun 24, 2013
Company News

Athera cardiovascular news

...€6 million ($8 million) to the CARDIMMUN consortium to develop the product through proof-of-concept development. Athera...
...is in late preclinical development. Karolinska Development AB (SSE:KDEV, Solna, Sweden) owns 65% of Athera. Athera Biotechnologies AB...
BioCentury | Oct 6, 2008
Company News

Athera, Dyax deal

...diseases such as atherosclerosis. Dyax will use its antibody libraries to generate human mAbs, and Athera...
...will have the option to further co-develop and commercialize candidates. Financial terms were not disclosed. Athera Biotechnologies AB...
Items per page:
1 - 9 of 9